Climb Bio Presents Initial PrisMN Phase 2 Data for Budoprutug at ASN Kidney Week 2026

Climb Bio, Inc. presented initial data from its PrisMN Phase 2 study of budoprutug at ASN Kidney Week 2026, showing that a low dose of 200 mg achieved B-cell depletion and a reduction in PLA2R antibodies at 12 weeks. These results align with prior Phase 1b data for the monoclonal antibody therapy aimed at treating immune-mediated diseases.